Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Summary

This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.

Eligibility

Inclusion Criteria:

* Pathologically diagnosed colorectal adenocarcinoma
* Age ≥18 years old and ≤75 years old
* MRI/CT stage T3-4aNany and TanyN1-2, without distant metastasis
* Life expectancy of 1 year The above
* Informed consent, no contraindications to chemotherapy exist
* pMMR diagnosed by IHC

Exclusion Criteria:

* Refused to participate in this study
* Multifocal colorectal cancer
* Past history of malignant tumors, except for basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ
* Unable to receive chemotherapy , such as but not limited to bone marrow suppression, etc
* Major organ diseases (such as but not limited to COPD, coronary heart disease and renal insufficiency, etc.) acute attack and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.),
* ASA score\> 3
* Mental disorder or illiteracy or language and communication barriers cannot understand the research plan
* Colorectal tumor has obstruction or high risk of obstruction and or there is bleeding and/or perforation
* Peripheral sensory nerve disorder, unable to receive oxaliplatin chemotherapy
* Lateral pelvic lymph node metastasis (mainly supplied by internal iliac artery)
* Pregnancy or breastfeeding
* Unable to accept MRI examination
* Consecutive use of glucocorticoids for more than 3 days within 1 month before signing the consent form
* Diabetes or impaired glucose tolerance who may require drug intervention
* Other scenarios deemed inappropriate by the investigators

Conditions2

Interventions4

Related trials

• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. — Zhejiang Cancer Hospital
• A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy — Jinling Hospital, China
• Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma — The First Affiliated Hospital of Soochow University
• Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma — Ze-yang Ding, MD
• Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma — Tongji Hospital
• IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors — Chinese PLA General Hospital
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer — Changhai Hospital
• Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Browse More Trials